Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS ...Middle East

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET)...

Hence then, the article about phase ii opalescence study of tlx250 cdx in triple negative breast cancer to be presented at sabcs was published today ( Wednesday 29/11/2023 - 11:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS )

Also on site :

• The C.I.A. Helped Pinpoint a Gathering of Iranian Leaders. Then Israel Struck.
• Former teacher at private school in Calabasas charged with annoying or molesting female students, secretly photographing them
• Ayatollah Ali Khamenei, Hard-Line Cleric Who Made Iran a Regional Power, Dies at 86